The DDX3 RNA helicase enzyme is highly multi-faceted in its activity and complex in its gene structure with ten highly conserved motives.
Our DDX3 inhibitors can be considered apoptosis-inducing targeted antitumor agents as they specifically induce cell death in those cancer cells.
The role of DDX3 in cancer is a subject of continues investigation by many research groups world wide.
First Health Pharmaceuticals’ cancer research concerns different types of cancer like breast-, lung-, prostate- and AIDS-associated cancers.
Substantial evidence supports the hypothesis of a presence of stem cells (or stem cell-like cells) amongst mature differentiated cancer cells.